These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 38602058)

  • 1. Exploring the tumor genomic landscape of aggressive prostate cancer by whole-genome sequencing of tissue or liquid biopsies.
    Weiss S; Lamy P; Rusan M; Nørgaard M; Ulhøi BP; Knudsen M; Kassentoft CG; Farajzadeh L; Jensen JB; Pedersen JS; Borre M; Sørensen KD
    Int J Cancer; 2024 Jul; 155(2):298-313. PubMed ID: 38602058
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Concordance of Circulating Tumor DNA and Matched Metastatic Tissue Biopsy in Prostate Cancer.
    Wyatt AW; Annala M; Aggarwal R; Beja K; Feng F; Youngren J; Foye A; Lloyd P; Nykter M; Beer TM; Alumkal JJ; Thomas GV; Reiter RE; Rettig MB; Evans CP; Gao AC; Chi KN; Small EJ; Gleave ME
    J Natl Cancer Inst; 2017 Dec; 109(12):. PubMed ID: 29206995
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genomic Analysis of Circulating Tumor DNA in 3,334 Patients with Advanced Prostate Cancer Identifies Targetable BRCA Alterations and AR Resistance Mechanisms.
    Tukachinsky H; Madison RW; Chung JH; Gjoerup OV; Severson EA; Dennis L; Fendler BJ; Morley S; Zhong L; Graf RP; Ross JS; Alexander BM; Abida W; Chowdhury S; Ryan CJ; Fizazi K; Golsorkhi T; Watkins SP; Simmons A; Loehr A; Venstrom JM; Oxnard GR
    Clin Cancer Res; 2021 Jun; 27(11):3094-3105. PubMed ID: 33558422
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Contrasting genomic profiles from metastatic sites, primary tumors, and liquid biopsies of advanced prostate cancer.
    Necchi A; Cucchiara V; Grivas P; Bratslavsky G; Jacob J; Spiess PE; Sokol ES; Killian JK; Lin D; Ramkissoon S; Huang RSP; Madison RW; Venstrom JM; Schrock AB; Danziger N; Decker B; Gjoerup O; Graf RP; Oxnard GR; Tukachinsky H; Ross JS
    Cancer; 2021 Dec; 127(24):4557-4564. PubMed ID: 34379803
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circulating Tumor DNA Abundance and Potential Utility in De Novo Metastatic Prostate Cancer.
    Vandekerkhove G; Struss WJ; Annala M; Kallio HML; Khalaf D; Warner EW; Herberts C; Ritch E; Beja K; Loktionova Y; Hurtado-Coll A; Fazli L; So A; Black PC; Nykter M; Tammela T; Chi KN; Gleave ME; Wyatt AW
    Eur Urol; 2019 Apr; 75(4):667-675. PubMed ID: 30638634
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Deep whole-genome ctDNA chronology of treatment-resistant prostate cancer.
    Herberts C; Annala M; Sipola J; Ng SWS; Chen XE; Nurminen A; Korhonen OV; Munzur AD; Beja K; Schönlau E; Bernales CQ; Ritch E; Bacon JVW; Lack NA; Nykter M; Aggarwal R; Small EJ; Gleave ME; ; Quigley DA; Feng FY; Chi KN; Wyatt AW
    Nature; 2022 Aug; 608(7921):199-208. PubMed ID: 35859180
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantitative and Qualitative Analysis of Blood-based Liquid Biopsies to Inform Clinical Decision-making in Prostate Cancer.
    Casanova-Salas I; Athie A; Boutros PC; Del Re M; Miyamoto DT; Pienta KJ; Posadas EM; Sowalsky AG; Stenzl A; Wyatt AW; Mateo J
    Eur Urol; 2021 Jun; 79(6):762-771. PubMed ID: 33422353
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evolution of the genomic landscape of circulating tumor DNA (ctDNA) in metastatic prostate cancer over treatment and time.
    Hahn AW; Stenehjem D; Nussenzveig R; Carroll E; Bailey E; Batten J; Maughan BL; Agarwal N
    Cancer Treat Res Commun; 2019; 19():100120. PubMed ID: 30743187
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Concordance and Clinical Significance of Genomic Alterations in Progressive Tumor Tissue and Matched Circulating Tumor DNA in Aggressive-variant Prostate Cancer.
    Wang R; Xu Q; Guo H; Yang G; Zhang J; Wang H; Xu T; Guo C; Yuan J; He Y; Zhang X; Fu H; Xu G; Zhao B; Xie J; Zhao T; Huang L; Zhang J; Peng B; Yao X; Yang B
    Cancer Res Commun; 2023 Nov; 3(11):2221-2232. PubMed ID: 37877742
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genomic analysis of Korean patients with advanced prostate cancer by use of a comprehensive next-generation sequencing panel and low-coverage, whole-genome sequencing.
    Kang M; Cho E; Jang J; Lee J; Jeon Y; Jeong BC; Seo SI; Jeon SS; Lee HM; Choi HY; Jeon HG
    Investig Clin Urol; 2019 Jul; 60(4):227-234. PubMed ID: 31294131
    [TBL] [Abstract][Full Text] [Related]  

  • 11.
    Warner E; Herberts C; Fu S; Yip S; Wong A; Wang G; Ritch E; Murtha AJ; Vandekerkhove G; Fonseca NM; Angeles A; Beigi A; Schönlau E; Beja K; Annala M; Khalaf D; Chi KN; Wyatt AW
    Clin Cancer Res; 2021 Mar; 27(6):1650-1662. PubMed ID: 33414135
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modeling clonal structure over narrow time frames via circulating tumor DNA in metastatic breast cancer.
    Weber ZT; Collier KA; Tallman D; Forman J; Shukla S; Asad S; Rhoades J; Freeman S; Parsons HA; Williams NO; Barroso-Sousa R; Stover EH; Mahdi H; Cibulskis C; Lennon NJ; Ha G; Adalsteinsson VA; Tolaney SM; Stover DG
    Genome Med; 2021 May; 13(1):89. PubMed ID: 34016182
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genomic mutation profiling using liquid biopsy in Korean patients with prostate cancer: Circulating tumor DNA mutation predicts the development of castration resistance.
    Yu J; Cho E; Choi J; Lim JE; Lee J; Kang M; Sung HH; Jeong BC; Seo SI; Jeon SS; Lee HM; Jeon HG
    Investig Clin Urol; 2021 Mar; 62(2):224-232. PubMed ID: 33660451
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hybrid capture-based genomic profiling of circulating tumor DNA from patients with estrogen receptor-positive metastatic breast cancer.
    Chung JH; Pavlick D; Hartmaier R; Schrock AB; Young L; Forcier B; Ye P; Levin MK; Goldberg M; Burris H; Gay LM; Hoffman AD; Stephens PJ; Frampton GM; Lipson DM; Nguyen DM; Ganesan S; Park BH; Vahdat LT; Leyland-Jones B; Mughal TI; Pusztai L; O'Shaughnessy J; Miller VA; Ross JS; Ali SM
    Ann Oncol; 2017 Nov; 28(11):2866-2873. PubMed ID: 28945887
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High concordance of actionable genomic alterations identified between circulating tumor DNA-based and tissue-based next-generation sequencing testing in advanced non-small cell lung cancer: The Korean Lung Liquid Versus Invasive Biopsy Program.
    Park S; Olsen S; Ku BM; Lee MS; Jung HA; Sun JM; Lee SH; Ahn JS; Park K; Choi YL; Ahn MJ
    Cancer; 2021 Aug; 127(16):3019-3028. PubMed ID: 33826761
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liquid biopsy detection of genomic alterations in pediatric brain tumors from cell-free DNA in peripheral blood, CSF, and urine.
    Pagès M; Rotem D; Gydush G; Reed S; Rhoades J; Ha G; Lo C; Fleharty M; Duran M; Jones R; Becker S; Haller M; Sinai CE; Goumnerova L; Golub TR; Love JC; Ligon KL; Wright KD; Adalsteinsson VA; Beroukhim R; Bandopadhayay P
    Neuro Oncol; 2022 Aug; 24(8):1352-1363. PubMed ID: 34984433
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of Circulating Tumor DNA for the Clinical Management of Metastatic Castration-Resistant Prostate Cancer: A Multicenter, Real-World Study.
    Dong B; Fan L; Yang B; Chen W; Li Y; Wu K; Zhang F; Dong H; Cheng H; Pan J; Zhu Y; Chi C; Dong L; Sha J; Li L; Yao X; Xue W
    J Natl Compr Canc Netw; 2021 May; 19(8):905-914. PubMed ID: 33990090
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Concordance of Genomic Alterations by Next-Generation Sequencing in Tumor Tissue versus Circulating Tumor DNA in Breast Cancer.
    Chae YK; Davis AA; Jain S; Santa-Maria C; Flaum L; Beaubier N; Platanias LC; Gradishar W; Giles FJ; Cristofanilli M
    Mol Cancer Ther; 2017 Jul; 16(7):1412-1420. PubMed ID: 28446639
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical utility of plasma-based digital next-generation sequencing in patients with advance-stage lung adenocarcinomas with insufficient tumor samples for tissue genotyping.
    Zugazagoitia J; Ramos I; Trigo JM; Palka M; Gómez-Rueda A; Jantus-Lewintre E; Camps C; Isla D; Iranzo P; Ponce-Aix S; García-Campelo R; Provencio M; Franco F; Bernabé R; Juan-Vidal O; Felip E; de Castro J; Sanchez-Torres JM; Faul I; Lanman RB; Garrido P; Paz-Ares L
    Ann Oncol; 2019 Feb; 30(2):290-296. PubMed ID: 30535340
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comprehensive Analysis of AR Alterations in Circulating Tumor DNA from Patients with Advanced Prostate Cancer.
    Ledet EM; Lilly MB; Sonpavde G; Lin E; Nussenzveig RH; Barata PC; Yandell M; Nagy RJ; Kiedrowski L; Agarwal N; Sartor O
    Oncologist; 2020 Apr; 25(4):327-333. PubMed ID: 32297439
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.